PMID- 22805271
OWN - NLM
STAT- Publisher
LR  - 20191120
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 66
IP  - 8
DP  - 2012 Aug
TI  - A 48-week study of amlodipine plus amiloride / hydrochlorothiazide vs. amlodipine 
      plus telmisartan in the treatment of hypertension.
PG  - 792-799
LID - 10.1111/j.1742-1241.2012.02943.x [doi]
AB  - Background:  Chinese Hypertension Intervention Efficacy (CHIEF) study is a 
      large-scale randomised clinical trial across China, which compares the efficacy 
      of two combination regimens in reducing cardiovascular events associated with 
      hypertension. Methods:  We reported the 48-week efficacy and tolerability of the 
      two antihypertensive regimens in participants from Shandong Province, China. 
      Eligible patients aged 50-79 years were randomised to receive amlodipine plus 
      amiloride/hydrochlorothiazide (Group A) or amlodipine plus telmisartan (Group B). 
      The doses of both regimens were titrated and other antihypertensive agents were 
      added subsequently to achieve a blood pressure (BP) goal (<140/90 mmHg for 
      general population, <130/80 mmHg for diabetics and <150/90 mmHg for elderly). 
      Efficacy variables included the changes of BP, control rates (the proportion of 
      patients achieving a BP goal), and response rates (the proportion of patients 
      achieving a BP goal or a reduction of BP >/=20/10 mmHg). Safety was assessed by 
      monitoring the incidence of adverse events (AEs). Results:  Of the 349 patients 
      enrolled, 314 were randomised and 291 completed the study (141 in Group A and 150 
      in Group B). At week 48, the BP was reduced by 28.77/15.55 mmHg in Group A and by 
      31.38/16.07 mmHg in Group B (p > 0.05 for comparisons between Group A and Group 
      B). The control rates (71.79% vs. 77.22%; p = 0.270) and response rates (79.49% 
      vs. 84.81%; p = 0.218) were also similar. For both regimens, the control rates in 
      diabetic patients were relatively lower (31.91% and 32.50%), while those in 
      elderly patients were pretty higher (90.74% and 97.62%). AEs were mild to 
      moderate in severity (17.95% vs. 12.66%, p = 0.193). Conclusion:  Both 
      combination regimens, amlodipine plus amiloride/hydrochlorothiazide and 
      amlodipine plus telmisartan, were effective and safe for the high-risk 
      hypertensive patients.
CI  - (c) 2012 Blackwell Publishing Ltd.
FAU - Lu, F
AU  - Lu F
AD  - Cardio-Cerebrovascular Control and Research Center, Institute of Basic Medicine, 
      Shandong Academy of Medical Sciences, Jinan, Shandong, China Department of 
      Geriatric Cardiology, Provincial Hospital Affiliated to Shandong University, 
      Jinan, Shandong, China Department of Cardiology, Jinan Central Hospital 
      Affiliated to Shandong University, Jinan, Shandong, China.
FAU - Zhao, Y
AU  - Zhao Y
FAU - Liu, Z
AU  - Liu Z
FAU - Sun, H
AU  - Sun H
FAU - Zhao, Y
AU  - Zhao Y
FAU - Sun, S
AU  - Sun S
FAU - Wang, S
AU  - Wang S
LA  - eng
PT  - Journal Article
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
EDAT- 2012/07/19 06:00
MHDA- 2012/07/19 06:00
CRDT- 2012/07/19 06:00
PHST- 2012/07/19 06:00 [entrez]
PHST- 2012/07/19 06:00 [pubmed]
PHST- 2012/07/19 06:00 [medline]
AID - 10.1111/j.1742-1241.2012.02943.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2012 Aug;66(8):792-799. doi: 10.1111/j.1742-1241.2012.02943.x.